A ddPCR panel that fits in one well sounds like a lab manager's dream — until you read the fine print. According to Inside Precision Medicine, Bio-Rad is putting its ddPLEX EGFR/KRAS/BRAF Mutation Detection Assay on a virtual roadshow this month, pitching it to research labs as a faster, cheaper alternative to sequencing for NSCLC variant profiling. We took a look at what's actually being claimed versus what's been demonstrated.
One well, thirty-seven variants
The kit, run on the QX600 Droplet Digital PCR system, is research-use-only. No clinical claims, no IVD pathway. In a single reaction, it reportedly quantifies 37 variants across EGFR, KRAS, and BRAF, paired with a mutation-agnostic total quantification well for variant allele frequency calculations. The pitch is workflow compression: get hotspot coverage from a liquid biopsy or FFPE input without spinning up an NGS run, at sensitivity levels droplet partitioning has historically delivered over qPCR. Bio-Rad is leading the conversation internally — Surbhi Jain, the panel's R&D lead, and Prithwish Pal, director of global product marketing for oncology, are the two voices on the broadcast.
Where the validation numbers actually land
Jain is set to present analytical data from an external validation study. The reported performance: 100% concordance with alternative reference methods in archived plasma cell-free DNA, and 96.5% concordance in FFPE specimens. The cfDNA number is clean. The FFPE gap, however, is the kind of friction labs should pressure-test before assuming this slots in as a drop-in replacement for their existing reflex workflow — FFPE is exactly where most NSCLC samples still originate, and a 3.5% discordance rate is not a rounding error. Nobody in the webinar announcement says which variants drove that gap, which is the first thing a molecular pathologist should ask during the live Q&A.
The comparison that matters isn't qPCR
The framework positions ddPCR as more sensitive and precise than qPCR, and faster and cheaper than next-generation sequencing. The qPCR part is largely settled — partitioning wins at low allele frequencies. The NGS comparison is the one lab directors should interrogate. ddPCR is closed-target. You only see what the panel targets. For a research workflow focused on a defined driver-mutation hotspot set in NSCLC, that's a deliberate trade-off, not a loss. Just don't let it get sold as sequencing with extra steps.
What to track
The session is scheduled for Thursday, October 16, 2025, at 08:00 PDT / 11:00 EDT / 17:00 CET, with a live Q&A. If you're evaluating whether this panel actually reduces your NGS reflex burden, the relevant question isn't whether ddPCR beats qPCR. It's whether a 37-variant RUO panel covers the reflex decision points your oncologists actually need — and whether Bio-Rad is preparing an IVD submission, which the announcement does not address. One is a workflow tool. The other is a clinical product. They are not the same conversation.